• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Haploidentical donor-derived memory CAR T cells: first in human experience and in vitro correlative study.

作者信息

Ukrainskaya Valeria, Molostova Olga, Shelikhova Larisa, Pershin Dmitriy, Kulakovskaya Elena, Volkov Dmitry, Rakhteenko Arina, Muzalevskii Yakov, Kazachenok Alexei, Brilliantova Varvara, Osipova Daria, Rubtsov Yury, Stepanov Alexey, Maschan Michael

机构信息

M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.

出版信息

Blood Adv. 2022 Oct 11;6(19):5582-5588. doi: 10.1182/bloodadvances.2021006262.

DOI:10.1182/bloodadvances.2021006262
PMID:35446932
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9577623/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1544/9577623/b768636fa5dd/BLOODA_ADV-2021-006262-gr2a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1544/9577623/78777a18c8b2/BLOODA_ADV-2021-006262-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1544/9577623/b768636fa5dd/BLOODA_ADV-2021-006262-gr2a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1544/9577623/78777a18c8b2/BLOODA_ADV-2021-006262-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1544/9577623/b768636fa5dd/BLOODA_ADV-2021-006262-gr2a.jpg

相似文献

1
Haploidentical donor-derived memory CAR T cells: first in human experience and in vitro correlative study.单倍体相合供体来源的记忆性嵌合抗原受体T细胞：首次人体经验及体外相关性研究
Blood Adv. 2022 Oct 11;6(19):5582-5588. doi: 10.1182/bloodadvances.2021006262.
2
Preventive infusion of donor-derived CAR-T cells after haploidentical transplantation: Two cases report.单倍体相合移植后预防性输注供体来源的嵌合抗原受体T细胞：两例报告
Medicine (Baltimore). 2019 Jul;98(29):e16498. doi: 10.1097/MD.0000000000016498.
3
Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature.供体来源的 CAR-T 细胞作为减轻强度预处理方案，用于治疗复发/难治性急性淋巴细胞白血病的单倍体相合干细胞移植：病例报告及文献复习。
J Immunother. 2018 Jul/Aug;41(6):306-311. doi: 10.1097/CJI.0000000000000233.
4
Adoptive T Cell Therapy Following Haploidentical Hematopoietic Stem Cell Transplantation.同种异体造血干细胞移植后过继性 T 细胞治疗。
Front Immunol. 2019 Aug 6;10:1854. doi: 10.3389/fimmu.2019.01854. eCollection 2019.
5
Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.供体来源的靶向CD19的T细胞输注可诱导复发的B细胞急性淋巴细胞白血病患者达到微小残留病阴性缓解，这些患者在单倍体造血干细胞移植后对供体淋巴细胞输注无反应。
Br J Haematol. 2017 Nov;179(4):598-605. doi: 10.1111/bjh.14923. Epub 2017 Oct 26.
6
Irradiated haploidentical donor leukocyte infusions as an adoptive immunotherapy strategy to induce host-versus-tumor effects.辐照单倍体相合供者白细胞输注作为一种过继性免疫治疗策略以诱导宿主抗肿瘤效应。
Tumori. 2011 Jul-Aug;97(4):522-31. doi: 10.1177/030089161109700418.
7
Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.异体嵌合抗原受体修饰细胞用于过继细胞疗法治疗癌症。
Expert Opin Biol Ther. 2014 Jul;14(7):947-54. doi: 10.1517/14712598.2014.900540. Epub 2014 Mar 24.
8
CAR-T Cells: A New Tool for Monitoring T-cell Alloreactivity?嵌合抗原受体T细胞（CAR-T）：监测T细胞同种异体反应性的新工具？
Transplantation. 2023 Sep 1;107(9):e220-e221. doi: 10.1097/TP.0000000000004710. Epub 2023 Aug 2.
9
Adoptive immunotherapy with haploidentical allogeneic peripheral blood lymphocytes following autologous bone marrow transplantation.自体骨髓移植后采用单倍体相合异基因外周血淋巴细胞进行过继性免疫治疗。
Exp Hematol. 2000 Nov;28(11):1225-31. doi: 10.1016/s0301-472x(00)00533-6.
10
Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation.单倍体相合 CD19/CD22 双特异性 CAR-T 细胞在单倍体相合造血干细胞移植后复发难治性成人 B-ALL 患者中诱导 MRD 阴性缓解。
J Hematol Oncol. 2019 Jun 10;12(1):57. doi: 10.1186/s13045-019-0741-6.

引用本文的文献

1
Universal CAR 2.0 to overcome current limitations in CAR therapy.通用 CAR 2.0 克服 CAR 疗法当前的局限性。
Front Immunol. 2024 Jun 19;15:1383894. doi: 10.3389/fimmu.2024.1383894. eCollection 2024.
2
Protein Tyrosine Phosphatase CD45 As an Immunity Regulator and a Potential Effector of CAR-T therapy.蛋白酪氨酸磷酸酶CD45作为一种免疫调节因子及嵌合抗原受体T细胞（CAR-T）疗法的潜在效应分子
Acta Naturae. 2023 Jul-Sep;15(3):17-26. doi: 10.32607/actanaturae.25438.

本文引用的文献

1
Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients.多处地点制备的抗 CD19 CAR-T 细胞可诱导 B 细胞恶性肿瘤患者获得高缓解率。
Nat Commun. 2021 Dec 10;12(1):7200. doi: 10.1038/s41467-021-27312-6.
2
Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.托珠单抗预防非霍奇金淋巴瘤患者抗 CD19 CAR-T 细胞治疗后免疫效应细胞相关神经毒性综合征。
Front Immunol. 2021 Oct 12;12:745320. doi: 10.3389/fimmu.2021.745320. eCollection 2021.
3
Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation.
抢先输注供体来源的抗CD19嵌合抗原受体T细胞，对异基因造血干细胞移植后微小残留病阳性的B淋巴细胞白血病复发显示出有前景的抗白血病效果。
Leukemia. 2022 Jan;36(1):267-270. doi: 10.1038/s41375-021-01351-w. Epub 2021 Jul 20.
4
Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy.整合批量和单细胞分析方法对制备 T 细胞群体进行分析，揭示了影响嵌合抗原受体 T 细胞疗法长期持久性的因素。
Cancer Discov. 2021 Sep;11(9):2186-2199. doi: 10.1158/2159-8290.CD-20-1677. Epub 2021 Apr 5.
5
Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL.儿童和青少年 B 细胞急性淋巴细胞白血病患者接受 CD19-CAR T 细胞治疗的长期随访。
J Clin Oncol. 2021 May 20;39(15):1650-1659. doi: 10.1200/JCO.20.02262. Epub 2021 Mar 25.
6
Safety and efficacy of the low-dose memory (CD45RA-depleted) donor lymphocyte infusion in recipients of αβ T cell-depleted haploidentical grafts: results of a prospective randomized trial in high-risk childhood leukemia.低剂量记忆性（CD45RA 缺失）供体淋巴细胞输注在αβ T 细胞去除的单倍体相合移植物受者中的安全性和有效性：高危儿童白血病前瞻性随机试验结果
Bone Marrow Transplant. 2021 Jul;56(7):1614-1624. doi: 10.1038/s41409-021-01232-x. Epub 2021 Feb 16.
7
Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后复发 B 细胞急性淋巴细胞白血病患者接受供者来源抗 CD19 CAR-T 细胞治疗与供者淋巴细胞输注的比较。
Bone Marrow Transplant. 2021 May;56(5):1056-1064. doi: 10.1038/s41409-020-01140-6. Epub 2020 Nov 24.
8
Acute Graft-Versus-Host Disease After Humanized Anti-CD19-CAR T Therapy in Relapsed B-ALL Patients After Allogeneic Hematopoietic Stem Cell Transplant.异基因造血干细胞移植后复发的B-急性淋巴细胞白血病患者接受人源化抗CD19嵌合抗原受体T细胞治疗后的急性移植物抗宿主病
Front Oncol. 2020 Sep 29;10:573822. doi: 10.3389/fonc.2020.573822. eCollection 2020.
9
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant.供者来源的 CD19 CAR-T 细胞治疗移植后复发的 CD19 阳性 B-ALL。
Leukemia. 2021 Jun;35(6):1563-1570. doi: 10.1038/s41375-020-01056-6. Epub 2020 Oct 19.
10
Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma.自动化制造自体 CD19 CAR-T 细胞治疗非霍奇金淋巴瘤。
Front Immunol. 2020 Aug 7;11:1941. doi: 10.3389/fimmu.2020.01941. eCollection 2020.